A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Inclusion Criteria:

- Provide written, informed consent to participate in the study and follow the study
procedures

- Karnofsky Performance Status (KPS) of at least 70

- Measurable disease per RECIST 1.1 criteria

- Histological confirmation of advanced (not amenable to curative surgery or radiation
therapy) or metastatic RCC with clear cell component including patients who may have
sarcomatoid features

- At least one International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
prognostic factors must be present to qualify as either intermediate or poor risk
renal cell carcinoma

- No prior systemic therapy (including neoadjuvant, adjuvant, or vaccine therapy) for
RCC

- Patients with stable brain metastases may be enrolled if certain criteria are met

- Archival tumor tissue available

Exclusion Criteria:

- Patients who have an active, known or suspected autoimmune disease

- Patients who have a known additional malignancy that is progressing or requires active
treatment

- Any tumor invading the superior vena cava (SVC) or other major blood vessels

- Any tumor invading the gastrointestinal (GI) tract or any evidence of endotracheal or
endobronchial tumor within 30 days prior to randomization

Other protocol defined inclusion/exclusion criteria could apply